Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is at least 18 years old;~2. Patient is male, infertile female, or female of childbearing potential practicing an acceptable method of preventing pregnancy;~3. Patient or legal representative is willing to give written informed consent;~4. Patient is capable of complying with protocol requirements, including all follow-up visits;~5. Patient has symptomatic claudication or rest pain without tissue loss (Rutherford Categories 2-4).~6. Patient has de novo or restenotic target lesion(s) in the common and/or external iliac artery;~7. Patient has one or more regions of stenosis ≥ 50% in the target vessel, based on visual estimate;~8. Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm;~9. Patient has adequate ipsilateral blood flow including at least one sufficient (\<50% stenotic) infrapopliteal run-off vessel not requiring intervention (per side to be intervened on).~10. Patient has a total target lesion length visually estimated to be ≤110 mm which can be treated with a maximum of three VIABAHN BX endoprostheses;~11. Patient has no more than two discrete ipsilateral lesions that can be treated with no more than three VIABAHN BX endoprostheses \[OR\] Patient has bilateral disease consisting of only one target lesion per side that can be treated with no more than a total of three VIABAHN BX endoprostheses;~12. Patient has the device advanced across the target lesion(s) and positioned for deployment.~Exclusion Criteria:~1. Patient has a life expectancy of less than 1 year;~2. Patient has a known allergy to stent graft components, including stainless steel or heparin;~3. Patient has a known intolerance to antiplatelet, anticoagulant, or thrombolytic medications that would prevent compliance with the protocol;~4. Patient has a condition (unrelated to the study) that is expected to require indefinite, or lifelong, anticoagulation~5. Patient has an uncorrected bleeding disorder (platelet count \< 80,000/µL);~6. Patient has severe chronic renal insufficiency (serum creatinine level \> 2.5mg/dL) and not on hemodialysis;~7. Patient has a known hypercoagulability that cannot be corrected;~8. Patient has evidence of a blood borne infection;~9. Patient has had vascular access/catheterization in the lower extremity within 30 days of study enrollment;~10. Patient has had a previous or planned coronary intervention within 30 days prior to enrollment in this study or required at time of study procedure;~11. Patient has had a previous or planned bypass surgery in the target leg, or a bypass that occurs at the time of the index procedure;~12. Patient is currently participating in this or another investigative clinical study.~13. Patient has a stent or stent graft located within or immediately adjacent (≤5mm) to study lesion(s);~14. Patient has evidence of angiographically visible thrombus within or adjacent to the target lesion(s);~15. Patient has aneurysmal dilation proximal or distal to the target lesion(s) that would interfere with the placement of the device;~16. Patient has a target lesion requiring atherectomy or any ablative device to facilitate stent delivery;~17. Patient has a target lesion situated in such a way that an implanted device will prevent blood flow or perfusion to the internal iliac artery if patent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gore VIABAHN BX (Type: EXPERIMENTAL): Balloon expandable stenting of iliac occlusive disease

Based on this trial design, predict the completion outcome and termination type (if applicable).